Close

Drug Research

Humanetics receives US DoD funding for Covid-19 drug development

Humanetics has received funding from the US Department of Defense (DoD) to carry out a series of studies with its novel drug candidate, BIO 300, for Covid-19. The US DoD researchers discovered the drug candidate to create radio-protective drugs for...

X-Chem Acquires IntelliSyn and Sister Company, AviSyn, to Extend and Streamline Drug Discovery Service Range

X-Chem, Inc. (X-Chem), the industry-leading provider of DNA-Encoded Library (DEL)-based discovery services, has acquired IntelliSyn, a Montreal-based drug discovery services company and its US-based sister company, AviSyn. The transaction will enable the Company to offer a complete, seamless solution...

BioMed X Institute starts new research project in drug delivery in collaboration with Janssen

German independent research institute BioMed X announces its new research project with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, which will strive to discover novel transport mechanisms in the human intestinal...

Enara and Boehringer Ingelheim sign oncology partnership

Enara and Boehringer Ingelheim have teamed up to discover and develop novel cancer immunotherapies against overlooked dark antigen targets. How could dark antigens improve the treatment of solid tumour cancers. UK-based Enara Bio has entered into a collaboration with German-headquartered...

Nexelis acquires the GSK vaccines clinical bioanalytical laboratory located in Germany

Nexelis, a portfolio company of Ampersand Capital Partners, and a leading provider of advanced assay development and laboratory testing services in the infectious, oncologic, and metabolic diseases fields, has signed an asset purchase agreement with GSK to acquire its...

Lilly, Merus Ink Up-to-$1.6B Bispecific Antibody Partnership vs. Cancer

Eli Lilly’s oncology-focused Loxo Oncology at Lilly will partner with Merus to develop up to three CD3-engaging T-cell re-directing bispecific antibody therapies, through a research collaboration and exclusive licensing agreement that could generate up to $1.6 billion for the...

ConserV Bioscience and Lawrence Livermore National Laboratory to Collaborate on Development of Broad-spectrum Coronavirus Vaccine

ConserV Bioscience Limited (“ConserV”), a clinical-stage biotechnology company focused on developing vaccines that protect against endemic and emergent infectious diseases and Lawrence Livermore National Laboratory (“LLNL”) have agreed to collaborate on the development of a broad-spectrum coronavirus vaccine. This collaboration...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read